Brink Therapeutics
Paris, FR · Founded 2024 · 11 employees on LinkedIn · 3 known investors
Brink Therapeutics is a TechBio company developing programmable integrases, a nuclease-free platform for precise, large-payload genomic insertion of therapeutic genes for cell and gene therapy. It combines directed evolution, metagenomics, and generative AI to engineer insertion enzymes for applications such as CAR-T manufacturing and correcting monogenic diseases, and works with pharma and biotech partners on licensing and co-development.
Founders & leadership
Brink Therapeutics was founded in 2024 by Jonathan Naccache.
Investors · 3
Competitors · 5
by search overlapStingraytx3 shared keywordsStingray Therapeutics develops Vizenpistat (SR-8541A), an ENPP1 inhibitor that blocks the ENPP1 innate immune checkpoint to reactivate the cGAS-STING pathway against cancer. The drug is in clinical trials across multiple oncology indications, including metastatic colorectal cancer, advanced solid tumors, and planned expansions into anal, prostate, and bone cancers.
virion3 shared keywordsVirion Therapeutics develops CD8+ T cell-based immunotherapies using genetically encoded checkpoint modifiers delivered with target-specific antigens via a viral vector platform, targeting cancers and chronic infectious diseases. Its lead product, VRON-0200, is in clinical development as a potential functional cure for chronic hepatitis B.
Relay3 shared keywordsRelay Therapeutics develops small-molecule therapeutics using its Dynamo platform, which combines experimental and computational methods to model protein motion and target proteins considered difficult to drug. Its pipeline focuses on precision oncology and genetic disease.
Remix Therapeutics3 shared keywordsRemix Therapeutics develops RNA reprogramming technology to treat various diseases and disorders. The company applies precision medicine approaches across oncology and other therapeutic areas.
Aro Biotherapeutics3 shared keywordsAro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.
Companies competing with Brink Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Brink Therapeutics do?
- Brink Therapeutics is a TechBio company developing programmable integrases, a nuclease-free platform for precise, large-payload genomic insertion of therapeutic genes for cell and gene therapy. It combines directed evolution, metagenomics, and generative AI to engineer insertion enzymes for applications such as CAR-T manufacturing and correcting monogenic diseases, and works with pharma and biotech partners on licensing and co-development.
- Who founded Brink Therapeutics?
- Brink Therapeutics was founded by Jonathan Naccache in 2024.
- Who are Brink Therapeutics's investors?
- Brink Therapeutics's investors include Kima Ventures, Breega, Kurma Partners.
- Where is Brink Therapeutics headquartered?
- Brink Therapeutics is headquartered in Paris, FR.